MoleculeMind raises over $100M Series A for AI protein design
What's the deal? MoleculeMind, a Chinese AI protein design platform, has closed a Series A round raising over $100 million. The company builds AI tools for protein design and optimisation, with applications spanning biopharmaceuticals, synthetic biology, and industrial uses.
The round drew a broad coalition of investors including Blue Bridge CapitalDealroom has a profile for this one. Try Dealroom →, Pudong Venture CapitalDealroom has a profile for this one. Try Dealroom →, COFCO Emerging Industry Fund, Oriental Fortune CapitalDealroom has a profile for this one. Try Dealroom →, Fosun ChuangfuDealroom has a profile for this one. Try Dealroom →, Guofang Venture Capital, Saifen Technology, Infinity GroupDealroom has a profile for this one. Try Dealroom →, Caixin Capital, and Zhengding Capital. Existing backers Cathay Biotech and Xinhang Capital also increased their positions.
Proceeds will fund the company's AI platform for protein design, aiming to accelerate drug discovery and protein engineering.
Why now? Capital is flowing steadily into AI-driven biotechnology platforms in China. Investors are betting on tools that can shorten R&D cycles and enable programmable biology — an area where breakthroughs in large language models and generative AI have opened new possibilities for molecular design.
What could go wrong? AI protein design remains an emerging field where commercial validation lags behind scientific promise. MoleculeMind will need to convert platform capabilities into real-world partnerships and revenue. Competition in the AI-bio sector is intensifying, with well-funded rivals in both China and the West racing toward similar goals.
The signal: A $100 million Series A is a sizeable bet on a breakout-stage company, underscoring how quickly investor appetite for AI-driven protein engineering is scaling in China. The syndicate's breadth — spanning pure-play funds like Blue Bridge Capital and Pudong Venture Capital alongside corporate investor Fosun Chuangfu and strategic backer Cathay Biotech — suggests MoleculeMind is being positioned at the intersection of pharma, industrial biotech, and synthetic biology rather than a single vertical.
Read more: en.tmtpost.com
